ClinVar Miner

Submissions for variant NM_000535.7(PMS2):c.1145-17delinsGGAG

dbSNP: rs1562637330
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000781739 SCV000920027 uncertain significance not specified 2018-01-29 criteria provided, single submitter clinical testing Variant summary: PMS2 c.1145-17delinsGGAG alters a non-conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing. 3/5 computational tools predict that this variant may create a novel 3' splicing acceptor site (Alamut). However, these predictions have yet to be confirmed by functional studies. The variant was absent from 264976 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.1145-17delinsGGAG in individuals affected with Lynch Syndrome and no experimental evidence demonstrating its impact on splicing and protein function have been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar. Based on the evidence outlined above, the variant was classified as uncertain significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.